

Xin Tao

Senior Associate
Washington, D.C.

Biography

With a strong understanding of life sciences, Xin Tao works closely with clients in the food and drug industries to navigate the evolving regulatory environments and develop innovative strategies to commercialize products made with emerging technologies both in the United States and China.

Xin's previous work experience as a research biochemist informs his science-based food and drug law practices. His unique ability in understanding and interpreting the complex scientific issues as they relate to the governing legal and regulatory requirements helps clients with all phases of product development, manufacturing, and marketing. His practice focuses on novel food and drug applications that require U.S. Food and Drug Administration (FDA) review and FDA Current Good Manufacturing Practices (cGMP) compliance for foods, dietary supplements, and pharmaceuticals.

Born and raised in China, Xin is well-equipped to assist global companies to adapt to China's National Medical Products Administration's (NMPA), formerly known as China Food and Drug Administration (CFDA), ever-changing regulatory regime. Xin is increasingly expanding his knowledge of California's Proposition 65 (Prop 65) as it pertains to his clients.

Xin is actively involved in a number of organizations



Phone

+1 202 637 6986

Fax

+1 202 637 5910

Email

xin.tao@hoganlovells.com

Languages

Mandarin

Practices

Food Law

Consumer Law

Pharmaceuticals and Biotechnology
Regulatory

Industries

Consumer

Life Sciences and Health Care

Areas of focus

that serve Chinese legal and life sciences professionals in Washington, D.C., including the Sino-American Pharmaceutical Professionals Association and the Washington, D.C. Chinese Legal Association. He is a frequent speaker and contributor to industry publications in both the United States and China.

During law school, Xin worked as a regulatory scientist at an international law firm and served as an executive editor of the *Georgetown Environmental Law Review*.

Representative experience

Obtained FDA's favorable review of intended uses of several novel food additives, generally recognized as safe substances, and food contact substances in foods and beverages.

Helped food and pharmaceutical companies develop effective regulatory compliance strategy when responding to FDA Form 483 observations/warning letters.

Developed legal strategies in helping consumer products companies and trade associations establish compliance with California's Proposition 65 warning.

Helped global life sciences companies respond to NMPA enforcement actions and advised on premarket strategy of new drug products in China.

Advised various private equity funds, investment banks, and global food and pharmaceutical companies in conducting FDA and NMPA compliance due diligence reviews.

Awards and rankings

- Excellent Service Award, *Sino-American Pharmaceutical Association*, 2016

Latest thinking and events

- Sponsorships and Speaking Engagements

Consumer Product Safety
Regulation

Medical Foods and Dietary
Supplements

Food Advertising and Regulation

Food Recalls

International Regulatory
Compliance

Food Legislation and Regulatory
Policy Development

Product Development and Approval

Food Compliance and Enforcement

Hogan Lovells China Desk

Regulatory Inspections and cGMP

Cell, Tissue, and Gene Therapies

Education and admissions

Education

J.D., Georgetown University Law
Center, 2012

M.S., Texas A&M University, 2009

B.S., Shanghai Jiaotong University,
2006

Bar admissions and qualifications

District of Columbia

Virginia (inactive)

- Introduction to Food Law and Regulation
- Insights
 - China to establish pharmaceutical patent linkage and restoration under U.S./China trade deal
- News
 - China adds 30 drugs to its "urgently needed" list
- Hogan Lovells Publications
 - California Chamber of Commerce Challenges the Proposition 65 Acrylamide Warning for Foods
- Sponsorships and Speaking Engagements
 - Medical Foods Workshop: Science, Regulation and Practical Aspects
- Published Works
 - China: Survival of the Fittest or Cheapest? *Update Magazine*